Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  RADIOPHARMACEUTICALS
A US & European Market Report

This report analyzes the US and the European markets for Radiopharmaceuticals in Millions of US$. The major product segments analyzed are Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. Annual forecasts are provided for each region for the period of 2006 through 2015. A six-year historic analysis is also provided for these markets with annual market analytics. The report profiles 82 companies including many key and niche players such as Actinium Pharmaceuticals, Inc., Advanced Medical Isotope Corporation, Alseres Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals, Bio-Nucleonics, Inc., Bracco Diagnostics, Inc., Cardinal Health, Inc., Cellectar, LLC., Cell Therapeutics, Inc., Covidien Imaging Solutions, Cytogen Corporation, Draximage Inc, GE Healthcare Limited, GlaxoSmithKline Plc, IBA Molecular North America, Inc., Immunomedics, Inc., Kimberly-Clark, Inc., Lantheus Medical Imaging, Inc, MDS Nordion, Molecular Insight Pharmaceuticals, Inc., Peregrine Pharmaceuticals, Inc., PETNET Pharmaceuticals, Inc., Pharmalucence, Inc., and Triad Isotopes, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1889  PAGES:    363
PRICE:    $3950  DATE:       February 2009
COMPANIES:  82  MARKET DATA TABLES:   105
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  RADIOPHARMACEUTICALS (Complete Report) Pages : 363   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS4$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
A. Diagnostic Radiopharmaceuticals.....I-3
  
   B. Therapeutic Radiopharmaceuticals.....I-4  
II. A US & EUROPEAN MARKET REPORT87$3000
  1. Industry Overview.....II-18 $550  
   A Quick Primer.....II-1
Key Market Trends.....II-1
Continuous Battle Against Cancer: A Key Driver for Growth.....II-1
Cancer Statistics: A Grim Prognosis.....II-1
Business Case for Radiopharmaceuticals Exemplified.....II-1
1$75
   Development of Newer Diagnostic Agents to Boost Growth.....II-2
Demographics & New Applications Offer Opportunities On a Platter.....II-2
Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance.....II-2
Widespread Awareness Among Practitioners & Patients: The Need of the Hour.....II-2
1$75
   Expansion of Molecular Imaging Platform is Key to Future Growth.....II-3
Molecular Imaging Agents: A Noteworthy Breakthrough.....II-3
1$75
   Growing Demand for PET to Drive Up Demand.....II-4
Introduction of SPECT/CT & PET/CT: Double Edged Weapons for Growth.....II-4
1$75
   Manufacturers Quick to Take Cue.....II-5
Promising Developments in Therapeutic Radiopharmaceuticals Underway.....II-5
Targeted Peptides & Alpha Emitters: The New Frontiers of Therapeutic
  Radiopharmaceuticals.....II-5
1$75
   International Collaborations Give a Thumbs Up to Drug Development.....II-6
Market Challenges.....II-6
High Costs of Drug Development Piques Manufacturers.....II-6
Supply Shortages: A Niggling Cause of Concern.....II-6
1$75
   Price Sensitivity & Competition from Alternatives Limit Market Potential.....II-7
Lack of Dosage Standards for Pediatric Patients’ Limits Radiopharmaceutical
  Efficacy.....II-7
Unfounded Fears of Radiation Exposure Hinder Growth.....II-7
Bottlenecks in Developing Markets.....II-7
1$75
   Market Share Statistics: In Retrospect.....II-8
Table 1: Global Market for Medical Diagnostics Imaging (2003): Percentage Share Breakdown of Value Sales by Leading Players – GE (Amersham), Schering, Daiichi, Bristol Myers Squibb, Mallinckrodt, Bracco, Guerbet, and Others (includes corresponding Graph/Chart).....II-8

Table 2: Global Market for Radiopharmaceutical Medical Diagnostics (2003): Percentage Revenue Market Share of Leading Players – Amersham, Bristol-Myers Squibb, Tyco/ Mallinckrodt, Inc and Others (includes corresponding Graph/Chart).....II-8

Table 3: Global Market for Radioimmunotherapy Products (2003): Percentage Share Breakdown of Value Sales of Zevalin and Bexxar.....II-8
1$150
  2. Product Overview.....II-912 $900  
   Nuclear Medicine: A Prelude.....II-9
Radiopharmaceuticals: A Definition.....II-9
Mechanism of Action.....II-9
1$75
   Application of Radiopharmaceuticals.....II-10
Classification of Radiopharmaceuticals.....II-10
Diagnostic Radiopharmaceuticals.....II-10
1$75
   Commonly Used Diagnostic Radiopharmaceutical Agents.....II-11
Major Isotopes and their Diagnostic Applications.....II-11
1$75
   Advantages.....II-121$75
   Classification.....II-13
Fluorodeoxy Glucose (FDG): A Rapidly Growing Diagnostic Radiopharmaceutical.....II-13
Molecular Imaging Modalities In Radiopharmaceutical Diagnostics.....II-13
Planar Imaging.....II-13
1$75
   PET: A Prime Growth Driver for FDG.....II-14
Advantages.....II-14
1$75
   Applications of PET.....II-15
Commonly used Radioisotopes in PET Scans.....II-15
Major PET Isotopes and their Applications.....II-15
1$75
   Single Photon Emission Computed Tomography (SPECT).....II-161$75
   Applications of SPECT.....II-17
Commonly used Radioisotopes in SPECT Scans.....II-17
Therapeutic Radiopharmaceuticals.....II-17
Characteristics of Therapeutic Radiopharmaceuticals.....II-17
1$75
   Commonly used Therapeutic Agents.....II-18
Major Isotopes and their Therapeutic Applications.....II-18
Radiopharmaceuticals for Thyroid Therapy.....II-18
Radiopharmaceuticals for Cancer Therapy.....II-18
Radiopharmaceuticals for Radiosynoviorthesis Therapy.....II-18
1$75
   Radiopharmaceuticals for Bone Pain Palliation Therapy.....II-19
A Peek Into Key Therapeutic Radiopharmaceuticals in Research Pipeline As of the Year
  2007.....II-19
1$75
   Radiopharmacy: A Key Link in the Distribution Chain.....II-20
1$75
  3. Regional Market Overview.....II-211 $75  
   Regional Market Overview.....II-21
1$75
  3a. The United States.....II-2120 $1350  
   A. Market Analysis.....II-21
Outlook.....II-21
Industry Structure.....II-21
Production Scenario.....II-21
Dependence On Imports.....II-21
1$75
   Regulatory Scenario.....II-22
Thorny Regulations Dampen Down New Product Development.....II-22
FDA’s Antidote.....II-22
1$75
   Radiopharmaceutical Reimbursement in the US: Who’s Under the Umbrella.....II-23
Diagnostic Radiopharmaceuticals Bundled As Supplies Under Medicare
  Reimbursements.....II-23
CMS Proposed Packaging of Zevalin & Bexxar into Diagnostic Radiopharmaceuticals
  Raises Eyebrows.....II-23
Implications.....II-23
1$75
   Recommendations.....II-24
Changes in Medicare Reimbursements Vetoed.....II-24
1$75
   CMS Proposes New HOPPS Guidelines for 2008.....II-25
(i) Bundling Radiology Drugs and Services.....II-25
(ii) Payment for Therapeutic Radiopharmaceuticals.....II-25
1$75
   (iii) PET/CT scans.....II-26
(IV) Cardiac CT and Coronary CTA Procedures.....II-26
(v) Conversion factor.....II-26
Reimbursement Issues for PET.....II-26
1$75
   PET Clinical Applications Reimbursed by CMS as of March 2008.....II-271$75
   Deficit Reduction Act (DRA) 2005: Creating a Storm in a Teacup.....II-281$75
   Impact of the DRA On Outpatient Imaging Centers: An Evaluation.....II-29
Market Overview.....II-29
Sanguine Growth On Cards.....II-29
1$75
   Expanding Diagnostic Applications Will Stimulate Future Growth.....II-30
Nuclear Cardiology Products Drive Up Diagnostic Radiopharmaceuticals Market.....II-30
Cardiovascular Imaging To Lead Volume Growth.....II-30
Table 4: US Diagnostic Radiopharmaceutical Agents Market (2007 & 2009): Breakdown of Procedure Volume By Imaging Procedure - SPECT (Cardiac, Others) and PET (In Thousands) (includes corresponding Graph/Chart).....II-30
1$150
   Table 5: US Market for Diagnostic Radiopharmaceuticals Agents (2008 & 2012): Percentage Share Breakdown of Value Sales for Cardiology and Non-Cardiology Applications.....II-31

Table 6: US Market for Cardiology Diagnostic Radiopharmaceuticals (2004 & 2007): Percentage Share Breakdown of SPECT Myocardial Perfusion Imaging (MPI) Procedure Volume by Imaging Agent - Cardiolite, Myoview and Others (includes corresponding Graph/Chart).....II-31
New Oncology, Neurology Agents to Boost Diagnostic Radiopharmaceuticals
  Market.....II-31
1$150
   Table 7: US Market for Non-Cardiology Diagnostic Radiopharmaceuticals Agents (2007 & 2009): Percentage Share Breakdown of Value Sales for Oncology and Non-Oncology Applications.....II-32
Price Erosion to Increase Installed Base of SPECT Scanners.....II-32
Table 8: Diagnostic Radiopharmaceutical Market in North America: Installed Base for SPECT and SPECT/CT Scanners in Units for Years 2006, 2008, 2010, 2012 & 2014 (includes corresponding Graph/Chart).....II-32
Installed Pet Scanners in US.....II-32
1$150
   US FDG Market.....II-33
Table 9: US FDG Market (2007 & 2009): Breakdown of Procedure Volume by Procedure Type – Oncology, Neurology and Cardiology (In 000s) (includes corresponding Graph/Chart).....II-33

Table 10: US FDG Radiopharmacy Market: Number of Doses, Unit Cost and Number of Nuclear Pharmacies for 2004, 2008 & 2012(P) (includes corresponding Graph/Chart).....II-33
1$150
   Focused R&D Efforts will Fuel Therapeutic Radiopharmaceuticals Market.....II-34
Market Share Statistics.....II-34
Table 11: US Market for Diagnostics Radiopharmaceuticals Agents (2007): Percentage Share Breakdown of Value Sales by Leading Players - Lantheus Medical Imaging, GE HealthCare, Mallinckrodt and Others (includes corresponding Graph/Chart).....II-34

Table 12: US Market for Cardiology Diagnostic Radiopharmaceutical Agents (2007): Percentage Share Breakdown of Value Sales by Leading Players - Lantheus Medical Imaging, GE HealthCare and Others (includes corresponding Graph/Chart).....II-34
1$150
   Table 13: US Market for Non-Cardiology Diagnostic Radiopharmaceutical Agents (2007): Percentage Share Breakdown of Value Sales by Leading Players - Mallinckrodt, GE HealthCare, Lantheus Medical Imaging and Others (includes corresponding Graph/Chart).....II-35

Table 14: US Market for Therapeutic Radiopharmaceuticals (2007): Percentage Share Breakdown of Value Sales by Key Radiotherapeutics - Bone Palliation, Non-Hodgkin's Lymphoma, Hyperthyroidism /Thyroid Cancer and Others (includes corresponding Graph/Chart).....II-35
1$150
   Table 15: US Market for Therapeutic Radiopharmaceutical Agents (2007): Percentage Share Breakdown of Value Sales by Leading Players - GE HealthCare, Mallinckrodt, Biogen-Idec, GlaxoSmithKline, Cytogen and Others (includes corresponding Graph/Chart).....II-36

Table 16: US FDG Market (2007): Percentage Share Breakdown of Leading Players by Number of Cyclotrons Operated – PETNet Solutions, Cardinal Health, IBA Molecular, Triad Isotopes and Others (includes corresponding Graph/Chart).....II-36

Table 17: US Market for Radiopharmaceutical Bone Palliation Procedures (2005): Percentage Share Breakdown by Key Radiotherapeutics - Metastron, Quadramet and Sr-89 (includes corresponding Graph/Chart).....II-36
1$150
   Radiopharmaceuticals Market – A Peek Into the Recent Past.....II-37
Table 18: US Market for Diagnostics Radiopharmaceuticals in the Recent Past (2001): Percentage Share Breakdown of Value Sales by Leading Players -Bristol Meyers Squibb (DuPont), Amersham, Mallinckrodt and Others (includes corresponding Graph/Chart).....II-37

Table 19: US Market for Cardiology Diagnostics Radiopharmaceuticals in the Recent Past (2001): Percentage Share Breakdown of Value Sales by Leading Players -Bristol Meyers Squibb (DuPont), Amersham, and Others (includes corresponding Graph/Chart).....II-37

Table 20: US Market for Therapeutic Radiopharmaceuticals in the Recent Past (2001): Percentage Share Breakdown of Value Sales by Leading Players - Amersham, Berlex Laboratories, Mallinckrodt and Others (includes corresponding Graph/Chart).....II-37
1$150
   Table 21: US Market for Radiopharmaceuticals in the Recent Past (2001): Percentage Share Breakdown of Value Sales by Diagnostic Procedures –Heart Imaging Procedures, Cancer Imaging Procedures and Neurological &Other Imaging Procedures (includes corresponding Graph/Chart).....II-38

Table 22: Radiopharmacy Market in the US (2001, 2003 & 2005): Percentage Breakdown of Revenues Generated by General Radiopharmacies and FDG Radiopharmacies (includes corresponding Graph/Chart).....II-38
1$150
   Table 23: US Market for Radiopharmacies in the Recent Past (2001): Percentage Share Breakdown of Value Sales by Leading Players - Syncor, Mallinckrodt, Central Pharmacy Services Inc, Amersham and Independents (includes corresponding Graph/Chart).....II-39
B. Market Analytics.....II-39
Table 24: US Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-39
1$150
   Table 25: US Historic Review for Radiopharmaceuticals for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2005 (includes corresponding Graph/Chart).....II-40

Table 26: US 10-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2006, 2009 & 2015.....II-40
1$150
  3b. Europe.....II-415 $575  
   A. Market Analysis.....II-41
Outlook.....II-41
Competitive Scenario.....II-41
Key Statistics.....II-41
Table 27: European Diagnostic Radiopharmaceuticals Market: Percentage Share Breakdown of Value Sales by Imaging Modalities - SPECT and PET for Years 2005, 2008 & 2012 (includes corresponding Graph/Chart).....II-41
Market Trends.....II-41
New Applications and Products Augur Good Market Prospects.....II-41
1$150
   Increasing PET and PET/CT Applications Will Kindle Growth.....II-42
B. Market Analytics.....II-42
Table 28: European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-42
1$150
   Table 29: European Historic Review for Radiopharmaceuticals by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2005 (includes corresponding Graph/Chart).....II-43

Table 30: European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-43
1$150
   Table 31: European Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2005 (includes corresponding Graph/Chart).....II-44

Table 32: European 10-Year Perspective for Radiopharmaceuticals by Geographic Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-44
1$150
   Table 33: European 10-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2006, 2009 & 2015.....II-45
1$150
  3ba. France.....II-462 $200  
   A. Market Analysis.....II-46
Outlook.....II-46
B. Market Analytics.....II-46
Table 34: French Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-46
1$150
   Table 35: French Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2005 (includes corresponding Graph/Chart).....II-47

Table 36: French 10-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2006, 2009 & 2015.....II-47
1$150
  3bb. Germany.....II-482 $200  
   A. Market Analysis.....II-48
Outlook.....II-48
B. Market Analytics.....II-48
Table 37: German Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-48
1$150
   Table 38: German Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2005 (includes corresponding Graph/Chart).....II-49

Table 39: German 10-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2006, 2009 & 2015.....II-49
1$150
  3bc. Italy.....II-502 $200  
   A. Market Analysis.....II-50
Outlook.....II-50
B. Market Analytics.....II-50
Table 40: Italian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-50
1$150
   Table 41: Italian Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2005 (includes corresponding Graph/Chart).....II-51

Table 42: Italian 10-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2006, 2009 & 2015.....II-51
1$150
  3bd. United Kingdom.....II-522 $200  
   A. Market Analysis.....II-52
Outlook.....II-52
Market Overview.....II-52
B. Market Analytics.....II-52
Table 43: UK Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-52
1$150
   Table 44: UK Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2005 (includes corresponding Graph/Chart).....II-53

Table 45: UK 10-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2006, 2009 & 2015.....II-53
1$150
  3be. Spain.....II-542 $200  
   A. Market Analysis.....II-54
Outlook.....II-54
B. Market Analytics.....II-54
Table 46: Spanish Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-54
1$150
   Table 47: Spanish Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2005 (includes corresponding Graph/Chart).....II-55

Table 48: Spanish 10-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2006, 2009 & 2015.....II-55
1$150
  3bf. Rest of Europe.....II-562 $200  
   A. Market Analysis.....II-56
Outlook.....II-56
Market Overview.....II-56
B. Market Analytics.....II-56
Table 49: Rest of Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-56
1$150
   Table 50: Rest of Europe Historic Review for Radiopharmaceuticals by Product Segment – Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2005 (includes corresponding Graph/Chart).....II-57

Table 51: Rest of Europe 10-Year Perspective for Radiopharmaceuticals by Product Segment – Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2006, 2009 & 2015.....II-57
1$150
  4. Research & Development Breakthroughs.....II-583 $225  
   Azaya, Texas University Collaborate for Liposomal Radiation Therapy.....II-58
Pharmacyclics Reveals Phase 1/2 Study of MGd Antibody Targeted Radiation
  Therapy.....II-58
Peregrine Explores Potential of Cotara® for Brain Cancer Treatment.....II-58
Scientists Develop New Manufacturing Technology For Cancer Diagnostic
  Radioisotopes.....II-58
1$75
   Avid Radiopharmaceuticals Exploits ExpIND to Speed AD Drug Research.....II-59
Scientists Commend Combination Therapy for Follicular Lymphoma Patients.....II-59
1$75
   Missouri University Develops New Cancer Radiotherapy Method.....II-60
AGH Researchers Develop New Radioactive Seed Therapy for Lung Cancer.....II-60
AnazaoHealth® Obtains US Patent for Novel Radiopharmaceutical Preparations.....II-60
INMAS Develops Ciprofloxacin Radiolabelling Kit.....II-60
1$75
  5. Product Innovations/Introductions.....II-614 $300  
   Medrad Mounts Intego™ PET Infusion System at UPMC.....II-61
IBA Molecular Announces the Launch of Cyclone ® 18 Twin.....II-61
Immunomedics Announces Pre-Clinical Results for its Combination
  Radioimmunotherapy.....II-61
Molecular Insight Develops New Radioiodinated Molecules.....II-61
Immunomedics Develops New Antibody for Radioimmunotherapy.....II-61
1$75
   Peregrine Pharmaceuticals Launches Anti-Cancer Agent in China.....II-62
GE Healthcare Introduces Proton Package For Radiation Therapy Planning.....II-62
GE Healthcare Expands Definium Series of Digital Radiographic Products.....II-62
GE Introduces New Platform for PET Radiopharmaceutical Production.....II-62
1$75
   Draximage Gains FDA Approval for HiCon Kit.....II-63
Nihon Medi-Physics Secures Production Approval for FDG Scan Injection.....II-63
FDA Proposes Rules and Regulations with Respect to Radioactive Drugs.....II-63
Schering Nordiska Launches Zevalin Radioimmunotherapy in Europe.....II-63
1$75
   Immunomedics Announces Advancement in Radioimmunotherapy Technology.....II-64
Nihon Launches Radiopharmaceutical Agent for Enabling Epilepsy Diagnosis.....II-64
1$75
  6. Recent Industry Activity.....II-6516 $850  
   Positron Concludes Dose Shield Acquisition.....II-65
Positron Licenses NuView to Sell Imaging Technologies and Dose Dispensing
  Devices.....II-65
Bracco Imaging, Marillion Pharmaceuticals to Develop Novel Cancer Treatment.....II-65
EUSA Pharma Concludes Cytogen Acquisition.....II-65
AMIC, CRS to Co-Produce Indium-111.....II-65
1$75
   AMIC, MU Partner to Produce Radioisotopes.....II-66
Bracco, Lantheus to Co-Promote CardioGen-82®.....II-66
Cell Therapeutics Submits sBLA for Use of Zevalin® in First-Line Therapy.....II-66
ANSTO, Siemens Ink $10m Partnership Deal.....II-66
Covidien Gets FDA Nod for Generic Myocardial Perfusion Imaging Kit.....II-66
Neoprobe, Draximage Collaborate Over Lymphoseek Distribution.....II-66
1$75
   GE Healthcare Gets FDA Nod For New PET/CT Scanner.....II-67
GE Healthcare, Gamma Medica-Ideas Ink Distribution Deal.....II-67
CIS-US Receives FDA Approval for Generic Choletec® Kit.....II-67
Cellectar Obtains Funds for Clinical Trials.....II-67
Lantheus Medical Completes Phase I Study Of Novel PET Imaging Tracer.....II-67
GE Healthcare, Cardinal Health Partner for Myoview™ Imaging Agent.....II-67
1$75
   Avista Capital Partners Acquires Medical Imaging Unit of Bristol-Myers.....II-68
Siemens Healthcare Opens Two Radiopharmacies in US.....II-68
Cardinal Health Plans to Offer Services to Support PET Clinical Trials.....II-68
MEDRAD Associates with PETNET to Ingeniously Deliver FDG.....II-68
1$75
   Triad Isotopes to Build Four Nuclear Pharmacies.....II-69
AREVA, NCI to Develop Cancer-fighting Radiopharmaceuticals.....II-69
NuView Signs Agreement with California University.....II-69
NuView Inks Exclusive Agreement with Philadelphia’s Jefferson University.....II-69
University of Missouri Health Care Enters Sole-Source Supply Contract with Mid-America
  Isotopes.....II-69
1$75
   Cardinal Health Expands Manufacturing Capabilities for PET Imaging Agents.....II-70
Jubilant Completes Draxis Acquisition.....II-70
Atomic Energy Closes Two Reactors.....II-70
IBA Plans to Acquire CIS BIO.....II-70
Ion Beam Announces Closure of TAEK Financing.....II-70
1$75
   IBA Receives Approval for New Radiopharmaceutical Production Facility in UK.....II-71
WILEX AG Signs Licensing and Marketing Deal with Ion Beam.....II-71
Ion Beam Partners with Lantheus to Distribute Neurolite®, Cardiolite® in
  Europe.....II-71
1$75
   EIS Eczacibasi to Acquire 50 Percent Stake in Monrol.....II-72
Siemens to Set up Multiple Radiopharmaceutical Facilities in India.....II-72
Siemens Plans to Establish Its First Molecular Imaging Centre in India.....II-72
Ion Beam, Hae Dong Expands South Korea’s PET Radiopharmaceutical Market.....II-72
1$75
   Bayer and FutureChem Enter Radiolabeling Technology Licensing Agreement.....II-73
Cyclopharm Signs Agreement to Establish PET Radiopharmacy.....II-73
R2 Solucoes to Produce FGD-18, Radiological Diagnostics.....II-73
Triad Acquires Four Radiopharmaceutical Companies.....II-73
1$75
   Triad Isotopes Acquires Regional Nuclear Pharmacies.....II-74
Triad Isotopes Merges with Diversified Pharmacy Group.....II-74
Molecular Insight Pharmaceuticals Acquires Radiopharmaceutical Facility In
  Texas.....II-74
GE Healthcare to Shelf Production of Products with Short-Lived Radioisotopes.....II-74
Draxis Health Files ANDA to Market Cardiac Imaging Agent.....II-74
Cell Therapeutics Acquires Zevalin® Lymphoma Drug.....II-74
Premier Signs Contracts with Mallinckrodt, Agfa, Berlex.....II-74
1$75
   ADMD Announces Patent Licensing for Preparing Actinium-225.....II-75
Bayer Schering Exercises Rights to License Avid's 18-F AV1/ZK Compound.....II-75
Covidien Signs Agreement with BioSynthema for Cancer Treatment Technology.....II-75
1$75
   IBA Signs Contract to Supply Cyclone® 30 to Indian DAE.....II-76
MDS Nordion, Ottawa University to Establish Molecular Imaging Center of
  Excellence.....II-76
STC.UNM, NuView Sign Exclusive Commercialization and Distribution Deal.....II-76
Bracco, ImaRx Ink Cross Licensing Deal.....II-76
GE Healthcare Signs Exclusive Distribution Deal with Draximage.....II-76
1$75
   DRAXIMAGE, Med Discovery Form Research Collaboration.....II-77
Schering Changes Corporate Identity to Bayer Schering Pharma AG.....II-77
IBA Establishes New Radiopharmaceuticals Production Facility.....II-77
IBA Receives Approval for Production of Radiopharmaceuticals at UK Facility.....II-77
IBA Establishes Production and R&D Center in Belgium.....II-77
1$75
   MDS Nordion to Expand Medical Imaging Agent Production in Europe.....II-78
MDS Nordion, Avid Radiopharmaceuticals Ink Collaborative Agreement.....II-78
MDS Nordion Establishes Centers of Excellence for TheraSphere® in Europe.....II-78
Peregrine Opens Facility in China.....II-78
1$75
   GE Healthcare Receives Approval for First Radiopharmacy Facility in India.....II-79
Nuclear Research Center of Iran Announces Production of technetium-99m.....II-79
MDS Nordion Begins Clinical Trials For TheraSphere®.....II-79
Dow Offers ChelaMed(SM) Radiopharmaceutical Services.....II-79
Eckert & Ziegler Sets Up New Company For Radiopharmaceutical Development.....II-79
IBA Molecular Collaborates with WILEX AG.....II-79
1$75
   IBA Molecular Kicks Off Radiopharmaceutical Facility in India.....II-80
Cardinal Health Acquires Syncor International.....II-80
1$75
  7. Focus on Select Players.....II-817 $525  
   Actinium Pharmaceuticals, Inc. (US).....II-81
Advanced Medical Isotope Corporation (US).....II-81
Alseres Pharmaceuticals, Inc (US).....II-81
Bayer HealthCare Pharmaceuticals (US).....II-81
1$75
   Bio-Nucleonics, Inc. (US).....II-82
Bracco Diagnostics, Inc. (US).....II-82
Cardinal Health, Inc (US).....II-82
1$75
   Cellectar, LLC. (US).....II-83
Cell Therapeutics, Inc. (US).....II-83
Covidien Imaging Solutions (US).....II-83
Cytogen Corporation (US).....II-83
1$75
   Draximage Inc (Canada).....II-84
GE Healthcare Limited (UK).....II-84
GlaxoSmithKline Plc (UK).....II-84
1$75
   IBA Molecular North America, Inc. (US).....II-85
Immunomedics, Inc. (US).....II-85
Kimberly-Clark, Inc. (US).....II-85
1$75
   Lantheus Medical Imaging, Inc (US).....II-86
MDS Nordion (Canada).....II-86
Molecular Insight Pharmaceuticals, Inc. (US).....II-86
Peregrine Pharmaceuticals, Inc. (US).....II-86
1$75
   PETNET Pharmaceuticals, Inc. (US).....II-87
Pharmalucence, Inc. (US).....II-87
Triad Isotopes, Inc. (US).....II-87
1$75
III. COMPETITIVE LANDSCAPE 262$995
  
Total Companies Profiled:82 (including Divisions/Subsidiaries - 104 )

Region/Country                 Players


The United States                55
Canada                            2
Japan                             3
Europe                           31
     France                       1
     Germany                      7
     The United Kingdom           5
     Italy                        2
     Spain                        1
     Rest of Europe              15 
Asia-Pacific (Excluding Japan)   12
Latin America                     
Africa                            1
Middle East
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.